Statistik Asas
| LEI | 549300VM3X1FYD4N9Z14 |
| CIK | 1124140 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Exact Sciences Corporation
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| August 6, 2025 |
SECOND AMENDMENT TO EMPLOYMENT AGREEMENT EXHIBIT 10.4 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This Second Amendment to Employment Agreement (this “Amendment”) is entered into as of August 5, 2025, by and between Exact Sciences Corporation, a Delaware corporation (the “Company”), and Brian Baranick (“Employee”). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Employment Agreement (as defined |
|
| August 6, 2025 |
SECOND AMENDMENT TO EMPLOYMENT AGREEMENT EXHIBIT 10.5 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This Second Amendment to Employment Agreement (this “Amendment”) is entered into as of August 5, 2025, by and between Exact Sciences Corporation, a Delaware corporation (the “Company”), and Aaron Bloomer (“Employee”). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Employment Agreement (as defined b |
|
| August 6, 2025 |
SECOND AMENDMENT TO EMPLOYMENT AGREEMENT EXHIBIT 10.7 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This Second Amendment to Employment Agreement (this “Amendment”) is entered into as of August 5, 2025, by and between Exact Sciences Corporation, a Delaware corporation (the “Company”), and Jacob Orville (“Employee”). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Employment Agreement (as defined b |
|
| August 6, 2025 |
EXHIBIT 99.1 Investor Contact: Derek Leckow Exact Sciences Corp. [email protected] 608-893-0009 Media Contact: Steph Spanos Exact Sciences Corp. [email protected] 608-556-4380 For Immediate Release Exact Sciences Announces Second Quarter 2025 Results Reports record revenue, improves adjusted EBITDA, raises full-year guidance Second quarter and recent highlights •Delivered |
|
| August 6, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35092 EXACT SCIENCES CORPORATION (Exact nam |
|
| August 6, 2025 |
EXHIBIT 99.2 Exact Sciences Announces Exclusive License with Freenome for Blood-Based Colorectal Cancer Screening Tests Exact Sciences acquires exclusive rights to current and future versions of Freenome’s blood-based colorectal cancer screening tests Freenome submitted the final module of the premarket approval application to the FDA for the first-version test Strengthens Exact Sciences’ leadersh |
|
| August 6, 2025 |
EXACT SCIENCES CORPORATION 2025 OMNIBUS LONG-TERM INCENTIVE PLAN Deferred Stock Unit Award Agreement EXHIBIT 10.3 EXACT SCIENCES CORPORATION 2025 OMNIBUS LONG-TERM INCENTIVE PLAN Deferred Stock Unit Award Agreement Granted To: #ParticipantName# Grant Date: #GrantDate# Number of Deferred Stock Units: #QuantityGranted# This Deferred Stock Unit Award Agreement (“Award Agreement”) is made between Exact Sciences Corporation, a Delaware corporation (the “Company”), and you, a Service Provider to the Co |
|
| August 6, 2025 |
THIRD AMENDMENT TO EMPLOYMENT AGREEMENT EXHIBIT 10.6 THIRD AMENDMENT TO EMPLOYMENT AGREEMENT This Third Amendment to Employment Agreement (this “Amendment”) is entered into as of August 5, 2025, by and between Exact Sciences Corporation, a Delaware corporation (the “Company”), and Sarah Condella (“Employee”). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Employment Agreement (as defined be |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| July 11, 2025 |
EXACT SCIENCES CORPORATION 2025 OMNIBUS LONG-TERM INCENTIVE PLAN Restricted Stock Award Agreement EXHIBIT 4.10 EXACT SCIENCES CORPORATION 2025 OMNIBUS LONG-TERM INCENTIVE PLAN Restricted Stock Award Agreement Granted To: Grant Date: Number of Restricted Stock Award: Fair Market Value Per Share: This Restricted Stock Award Agreement (“Award Agreement”) is made between Exact Sciences Corporation, a Delaware corporation (the “Company”) and you (“Grantee”). The Company sponsors the 2025 Omnibus Lo |
|
| July 11, 2025 |
As filed with the Securities and Exchange Commission on July 11, 2025 As filed with the Securities and Exchange Commission on July 11, 2025 Registration No. |
|
| July 11, 2025 |
EXHIBIT 4.9 EXACT SCIENCES CORPORATION 2025 OMNIBUS LONG-TERM INCENTIVE PLAN Performance Share Unit (PSU) Award Agreement Grantee: Grant Date: Maximum Number of Performance Share Units (PSUs): Target Number of Performance Share Units (PSUs): This Global Performance Share Unit Award Agreement, including any country-specific terms and conditions set forth in Exhibit B hereto (the “Award Agreement”) |
|
| July 11, 2025 |
EXHIBIT 107.1 Calculation of Filing Fee Tables ……Form S-8…….. (Form Type) …………….…………… Exact Sciences Corporation ………………………….. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offeri |
|
| July 11, 2025 |
As filed with the Securities and Exchange Commission on July 11, 2025 As filed with the Securities and Exchange Commission on July 11, 2025 Registration No. |
|
| July 11, 2025 |
EXHIBIT 4.8 EXACT SCIENCES CORPORATION 2025 OMNIBUS LONG-TERM INCENTIVE PLAN Restricted Stock Unit Award Agreement Granted To: Grant Date: Number of Restricted Stock Units: This Global Restricted Stock Unit Award Agreement, including any country-specific terms and conditions set forth in Exhibit B hereto (the “Award Agreement”) is made between Exact Sciences Corporation, a Delaware corporation (th |
|
| June 24, 2025 |
Table of Contents United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2024 OR ☐ TRANSITION REPORT PUR |
|
| June 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 16, 2025 |
EXACT SCIENCES CORPORATION 2025 OMNIBUS LONG-TERM INCENTIVE PLAN EXHIBIT 10.1 EXACT SCIENCES CORPORATION 2025 OMNIBUS LONG-TERM INCENTIVE PLAN Exact Sciences Corporation, a Delaware corporation (the “Company”), sets forth herein the terms of its 2025 Omnibus Long-Term Incentive Plan (as may be amended from time to time, the “Plan”), as follows: 1. PURPOSE The Plan is intended to enhance the Company’s and its Affiliates’ (as defined herein) ability to attract an |
|
| June 16, 2025 |
EXHIBIT 10.2 AMENDMENT TO EXACT SCIENCES CORPORATION 2010 EMPLOYEE STOCK PURCHASE PLAN (As amended and restated on July 31, 2024) AMENDMENT (the "Amendment"), dated April 15, 2025, to the 2010 Employee Stock Purchase Plan (As amended and restated on July 31, 2024) (the "Existing Plan"; as amended hereby, the "Plan"), of EXACT SCIENCES CORPORATION, a Delaware corporation (the "Company"). Statement |
|
| May 1, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2025 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 1, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35092 EXACT SCIENCES CORPORATION (Exact na |
|
| May 1, 2025 |
Exact Sciences Announces First-Quarter 2025 Results EXHIBIT 99.1 Investor Contact: Derek Leckow Exact Sciences Corp. [email protected] 608-893-0009 Media Contact: Steph Spanos Exact Sciences Corp. [email protected] 608-556-4380 For Immediate Release Exact Sciences Announces First-Quarter 2025 Results First quarter highlights •Delivered total first quarter revenue of $707 million, an increase of 11% on a reported and core r |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2025 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ |
|
| February 19, 2025 |
Exact Sciences Announces Fourth Quarter 2024 Results EXHIBIT 99.1 Investor Contact: Derek Leckow Exact Sciences Corp. [email protected] 608-893-0009 Media Contact: Steph Spanos Exact Sciences Corp. [email protected] 608-556-4380 For Immediate Release Exact Sciences Announces Fourth Quarter 2024 Results Fourth quarter and 2024 highlights •Total fourth quarter revenue of $713 million, an increase of 10%, or 11% on a core reve |
|
| February 19, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-35092 EXACT SCIENCES CORPORATION (Exact name of re |
|
| February 19, 2025 |
EXACT SCIENCES CORPORATION INSIDER TRADING POLICY EXHIBIT 19 EXACT SCIENCES CORPORATION INSIDER TRADING POLICY Exact Sciences Corporation (“Exact”) has adopted this Insider Trading Policy (the “Policy”) to promote compliance with federal securities laws by members of Exact’s Board of Directors, officers, employees, contractors and consultants of Exact and its affiliates, as well as any immediate family members sharing the household of any of the foregoing, and any entities controlled by any of the foregoing persons, including corporations, partnerships or trusts (collectively, “Exact Personnel”). |
|
| February 19, 2025 |
SUBSIDIARIES OF EXACT SCIENCES CORPORATION EXHIBIT 21 SUBSIDIARIES OF EXACT SCIENCES CORPORATION Registrant’s consolidated subsidiaries are shown below, together with the state or jurisdiction of organization of each subsidiary and the percentage of voting securities that Registrant owns in each subsidiary. |
|
| February 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2025 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| February 19, 2025 |
Exact Sciences Corporation Executive Officer Perquisite Policy Exact Sciences Corporation Executive Officer Perquisite Policy This Exact Sciences Corporation (the “Company”) Perquisite Policy (the “Policy”), effective December 13, 2024, sets forth the Company’s perquisite policy for Executive Officers. |
|
| February 19, 2025 |
Exact Sciences Corporation Non-Employee Director Compensation Policy EXHIBIT 10.30 Exact Sciences Corporation Non-Employee Director Compensation Policy The purpose of this Non-Employee Director Compensation Policy of Exact Sciences Corporation, a Delaware corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high caliber directors who are not employees or officers of the Company |
|
| February 10, 2025 |
JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Exact Sciences Corporation is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to the Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. |
|
| January 13, 2025 |
EXHIBIT 10.1 CREDIT AGREEMENT dated as of January 13, 2025 among EXACT SCIENCES CORPORATION, as the Borrower, THE LENDERS FROM TIME TO TIME PARTY HERETO JPMORGAN CHASE BANK, N.A., as Administrative Agent, and JPMORGAN CHASE BANK, N.A., BOFA SECURITIES, INC. and PNC BANK, NATIONAL ASSOCIATION, As Joint Lead Arrangers and Joint Bookrunners and CIBC BANK USA, CITIBANK, N.A., CRÉDIT AGRICOLE CORPORATE |
|
| January 13, 2025 |
Exact Sciences Announces Preliminary Fourth Quarter 2024 Results EXHIBIT 99.1 Investor Contact: Erik Holznecht Exact Sciences Corp. [email protected] 608-535-8659 Media Contact: Steph Spanos Exact Sciences Corp. [email protected] 608-556-4380 For Immediate Release Exact Sciences Announces Preliminary Fourth Quarter 2024 Results Highlighted announcements: •Expects total fourth quarter revenue of $713 million, an increase of 10% compared |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2025 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2025 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 13, 2024 |
EXAS / Exact Sciences Corporation / Capital World Investors - SEC SCHEDULE 13G Passive Investment SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Exact Sciences Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 30063P105 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d |
|
| November 8, 2024 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Exact Sciences Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 30063P105 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriat |
|
| November 8, 2024 |
EX-99 2 Rule13DJointFilingAgreement.htm JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Exact Sciences Corporation is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d- |
|
| November 5, 2024 |
EXHIBIT 10.5 EXACT SCIENCES CORPORATION 2010 EMPLOYEE STOCK PURCHASE PLAN (As amended and restated on July 31, 2024) Article 1—Purpose. This 2010 Employee Stock Purchase Plan, as amended and restated (the "Plan"), is intended to encourage stock ownership by all eligible employees of Exact Sciences Corporation (the "Company"), a Delaware corporation, and its Participating Subsidiaries (as defined i |
|
| November 5, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35092 EXACT SCIENCES CORPORATION (Exac |
|
| November 5, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2024 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 5, 2024 |
FIRST AMENDMENT TO EMPLOYMENT AGREEMENT EXHIBIT 10.3 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This First Amendment to Employment Agreement (this “Amendment”) is entered into as of July 31, 2024, by and between Exact Sciences Corporation, a Delaware corporation (the “Company”), and Brian Baranick. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Employment Agreement (as defined below). RECITALS |
|
| November 5, 2024 |
SECOND AMENDMENT TO EMPLOYMENT AGREEMENT EXHIBIT 10.4 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This Second Amendment to Employment Agreement (this “Amendment”) is entered into as of July 31, 2024, by and between Exact Sciences Corporation, a Delaware corporation (the “Company”), and Sarah Condella. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Employment Agreement (as defined below). RECITA |
|
| November 5, 2024 |
EXHIBIT 99.1 Investor Contact: Erik Holznecht Exact Sciences Corp. [email protected] 608-535-8659 Media Contact: Steph Spanos Exact Sciences Corp. [email protected] 608-556-4380 For Immediate Release Exact Sciences Announces Third-Quarter 2024 Results Delivered record revenue and cash flow, improved adjusted EBITDA, advanced pipeline Third quarter highlights •Total third |
|
| November 5, 2024 |
FIRST AMENDMENT TO EMPLOYMENT AGREEMENT EXHIBIT 10.2 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This First Amendment to Employment Agreement (this “Amendment”) is entered into as of July 31, 2024, by and between Exact Sciences Corporation, a Delaware corporation (the “Company”), and Jacob Orville. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Employment Agreement (as defined below). RECITALS |
|
| November 5, 2024 |
FIRST AMENDMENT TO EMPLOYMENT AGREEMENT EXHIBIT 10.1 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This First Amendment to Employment Agreement (this “Amendment”) is entered into as of July 31, 2024, by and between Exact Sciences Corporation, a Delaware corporation (the “Company”), and Aaron Bloomer. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Employment Agreement (as defined below). RECITALS |
|
| October 4, 2024 |
MDXH / MDxHealth SA / Exact Sciences Corp - SC 13G Passive Investment SC 13G 1 exas-20241004xsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.) * MDXHEALTH SA (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) B5950S113 (CUSIP Number) September 27, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate bo |
|
| October 4, 2024 |
JOINT FILING AGREEMENT MDxHealth SA EX-99.1 2 exas-20241004xex991.htm EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT MDxHealth SA In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby confirm the agreement by and among them to the joint filing on behalf of them of the Statement on Schedule 13G and any and all further amendments thereto, with respect to the se |
|
| July 31, 2024 |
EXHIBIT 99.1 Investor Contact: Erik Holznecht Exact Sciences Corp. [email protected] 608-535-8659 Media Contact: Morry Smulevitz Exact Sciences Corp. [email protected] 608-345-8010 For Immediate Release Exact Sciences Announces Second-Quarter 2024 Results Reports record results, screened more than 1 million people with Cologuard®, raises adjusted EBITDA guidance Second |
|
| July 31, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35092 EXACT SCIENCES CORPORATION (Exact nam |
|
| July 31, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2024 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 25, 2024 |
Table of Contents United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023 OR ☐ TRANSITION REPORT PUR |
|
| June 17, 2024 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2024 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 7, 2024 |
SC 13G/A 1 EXACTSCIENCESCORPORATION.htm FILING EXACT SCIENCES CORPORATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 02)* EXACT SCIENCES CORPORATION (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 30063P105 (CUSIP Number) May 31, 2024 (Date of Event Which Requi |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2024 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 8, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 8, 2024 |
EXACT SCIENCES CORPORATION 5,570,132 Shares of Common Stock Table of Contents PROSPECTUS SUPPLEMENT (To prospectus dated May 25, 2023) EXACT SCIENCES CORPORATION 5,570,132 Shares of Common Stock This prospectus supplement relates to the resale of up to 5,570,132 shares of our common stock, par value $0. |
|
| May 8, 2024 |
Calculation of Filing Fee Tables ……424(b)(7)…….. (Form Type) …………….…………… Exact Sciences Corporation ………………………….. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum (2) Aggregate Offering Price |
|
| May 8, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35092 EXACT SCIENCES CORPORATION (Exact na |
|
| May 8, 2024 |
Exact Sciences Announces First-Quarter 2024 Results EXHIBIT 99.1 Investor Contact: Nathan Harrill Exact Sciences Corp. [email protected] 608-535-8659 Media Contact: Morry Smulevitz Exact Sciences Corp. [email protected] 608-345-8010 For Immediate Release Exact Sciences Announces First-Quarter 2024 Results First quarter highlights •Delivered total first quarter revenue of $638 million, an increase of 6% on a reported and |
|
| May 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 8, 2024 |
EXHIBIT 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (“Agreement”) is entered into effective as of April 15, 2024 (the “Effective Date”), by and between Aaron Bloomer (“Employee”) and Exact Sciences Corporation, a Delaware corporation (the “Company,” and together with Employee, the “Parties”). WHEREAS, the Company desires to employ Employee as its Chief Financial Officer, and Employee desir |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2024 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 17, 2024 |
EXHIBIT 4.2 EXACT SCIENCES CORPORATION 1.75% Convertible Senior Notes due 2031 FIFTH SUPPLEMENTAL INDENTURE Dated as of April 17, 2024 to INDENTURE Dated as of January 17, 2018 U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee TABLE OF CONTENTS Page ARTICLE 1 Scope of Fifth Supplemental Indenture; Definitions 1 SECTION 1.01. Scope of Fifth Supplemental Indenture 1 SECTION 1.02. Definitions |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2024 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 17, 2024 |
Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes EXHIBIT 99.1 Investor Contact: Nathan Harrill Exact Sciences Corp. [email protected] 608-535-8659 Media Contact: Morry Smulevitz Exact Sciences Corp. [email protected] 608-345-8010 For Immediate Release Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes MADISON, Wis., April 11, 2024 — Exact Sciences Corp. (Nasdaq: EXAS) (the “Co |
|
| April 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2024 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 15, 2024 |
Exact Sciences Names Aaron Bloomer as New Chief Financial Officer Exact Sciences Names Aaron Bloomer as New Chief Financial Officer MADISON, Wisc., April 15, 2024 – Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today the appointment of Aaron Bloomer as chief financial officer (CFO), effective May 15, 2024. Mr. Bloomer brings to Exact Sciences more than 15 years of finance and accounting experience. He previ |
|
| February 21, 2024 |
SUBSIDIARIES OF EXACT SCIENCES CORPORATION EXHIBIT 21 SUBSIDIARIES OF EXACT SCIENCES CORPORATION Registrant’s consolidated subsidiaries are shown below, together with the state or jurisdiction of organization of each subsidiary and the percentage of voting securities that Registrant owns in each subsidiary. |
|
| February 21, 2024 |
EXACT SCIENCES CORPORATION EQUITY AWARD DEATH, DISABILITY AND RETIREMENT POLICY EXHIBIT 10.33 EXACT SCIENCES CORPORATION EQUITY AWARD DEATH, DISABILITY AND RETIREMENT POLICY 1.Introduction. This Equity Award Death, Disability and Retirement Policy, as amended (the “Policy”), specifies the treatment of each outstanding equity award (an “Equity Award”) granted by Exact Sciences Corporation, a Delaware corporation (including any successor thereto, the “Company”), in the event of |
|
| February 21, 2024 |
EXACT SCIENCES CORPORATION INCENTIVE-BASED COMPENSATION RECOVERY POLICY EXHIBIT 97 EXACT SCIENCES CORPORATION INCENTIVE-BASED COMPENSATION RECOVERY POLICY 1. |
|
| February 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2024 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| February 21, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-35092 EXACT SCIENCES CORPORATION (Exact name of re |
|
| February 21, 2024 |
EXHIBIT 99.1 Investor Contact: Nathan Harrill Exact Sciences Corp. [email protected] 608-535-8659 Media Contact: Morry Smulevitz Exact Sciences Corp. [email protected] 608-345-8010 For Immediate Release Exact Sciences Announces Fourth Quarter 2023 Results Reports record revenue, generates positive free cash flow, expects 2024 revenue of $2.810-2.850 billion Fourth quar |
|
| February 13, 2024 |
EXAS / Exact Sciences Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0891-exactsciencescorp.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* Name of issuer: Exact Sciences Corp Title of Class of Securities: Common Stock CUSIP Number: 30063P105 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to design |
|
| February 9, 2024 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* EXACT SCIENCES CORPORATION (Name of Issuer) Common Stock (Title of Class of Securities) 30063P105 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| January 23, 2024 |
SC 13G/A 1 EXACTSCIENCESCORPORATION.htm FILING EXACT SCIENCES CORPORATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 01)* EXACT SCIENCES CORPORATION (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 30063P105 (CUSIP Number) December 29, 2023 (Date of Event Which |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2024 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 8, 2024 |
EXHIBIT 99.1 Investor Contact: Nathan Harrill Exact Sciences Corp. [email protected] 608-535-8659 Media Contact: Morry Smulevitz Exact Sciences Corp. [email protected] 608-345-8010 For Immediate Release Exact Sciences Announces Preliminary Fourth Quarter 2023 Results Anticipates record fourth-quarter revenue, expects full-year 2024 revenue of $2.83 billion, submits nex |
|
| November 1, 2023 |
EXHIBIT 99 Investor Contact: Erik Holznecht Exact Sciences Corp. [email protected] 608-800-6605 Media Contact: Morry Smulevitz Exact Sciences Corp. [email protected] 608-345-8010 For Immediate Release Exact Sciences Announces Third-Quarter 2023 Results Reports record revenue, delivers more than a million test results, raises full-year guidance Third-quarter 2023 highli |
|
| November 1, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35092 EXACT SCIENCES CORPORATION (Exac |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2023 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission |
|
| October 10, 2023 |
SC 13G 1 EXACTSCIENCESCORPORATION.htm FILING EXACT SCIENCES CORPORATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* EXACT SCIENCES CORPORATION (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 30063P105 (CUSIP Number) September 29, 2023 (Date of Event Which Req |
|
| August 1, 2023 |
As filed with the Securities and Exchange Commission on August 1, 2023 As filed with the Securities and Exchange Commission on August 1, 2023 Registration No. |
|
| August 1, 2023 |
Exhibit 99 Investor Contact: Megan Jones Exact Sciences Corp. [email protected] 608-535-8815 Media Contact: Morry Smulevitz Exact Sciences Corp. [email protected] 608-345-8010 For Immediate Release Exact Sciences Announces Second-Quarter 2023 Results Reports record results, generates positive free cash flow, raises full-year guidance Second-quarter 2023 highlights •Total seco |
|
| August 1, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35092 EXACT SCIENCES CORPORATION (Exact nam |
|
| August 1, 2023 |
EXHIBIT 107.1 Calculation of Filing Fee Tables ……Form S-8…….. (Form Type) …………….…………… Exact Sciences Corporation ………………………….. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offeri |
|
| August 1, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2023 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 1, 2023 |
EXHIBIT 10.5 EXACT SCIENCES CORPORATION 2019 OMNIBUS LONG-TERM INCENTIVE PLAN, AS AMENDED Deferred Stock Unit Award Agreement GRANTED TO GRANT DATE NUMBER OF DEFERRED STOCK UNITS This Deferred Stock Unit Award Agreement (“Award Agreement”) is made between Exact Sciences Corporation, a Delaware corporation (the “Company”), and you, a Service Provider to the Company. The Company maintains the Exact |
|
| August 1, 2023 |
EXHIBIT 10.4 EXACT SCIENCES CORPORATION 2019 OMNIBUS LONG-TERM INCENTIVE PLAN, AS AMENDED Restricted Stock Award Agreement GRANTED TO GRANT DATE NUMBER OF SHARES This Restricted Stock Award Agreement (“Award Agreement”) is made between Exact Sciences Corporation, a Delaware corporation, (the “Company”) and you (“Grantee”). The Company sponsors the 2019 Omnibus Long-Term Incentive Plan, as amended |
|
| August 1, 2023 |
Exact Sciences Corporation Incentive Stock Option Award Agreement Cover Sheet EXHIBIT 10.2 Exact Sciences Corporation Incentive Stock Option Award Agreement Cover Sheet Exact Sciences Corporation, a Delaware corporation, hereby grants to you (the Grantee named below), and you hereby accept, an Option on the following terms and subject to the terms and conditions specified in the attached Terms and Conditions Controlling Plan: Exact Sciences Corporation 2019 Omnibus Long-Ter |
|
| August 1, 2023 |
Exhibit 10.3 EXACT SCIENCES CORPORATION 2019 OMNIBUS LONG-TERM INCENTIVE PLAN, AS AMENDED Restricted Stock Unit Award Agreement Granted To: Grant Date: Number of Restricted Stock Units: This Restricted Stock Unit Award Agreement (“Award Agreement”) is made between Exact Sciences Corporation, a Delaware corporation (the “Company”), and you, a Service Provider to the Company (“Grantee”). The Company |
|
| June 27, 2023 |
Table of Contents United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022 OR ☐ TRANSITION REPORT PUR |
|
| June 21, 2023 |
exas-20230621ex991 June 21, 2023 We aim to eradicate cancer with tests that help prevent it, detect it earlier, and guide treatment. |
|
| June 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 12, 2023 |
EXHIBIT 3.1 CERTIFICATE OF AMENDMENT TO SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF EXACT SCIENCES CORPORATION EXACT SCIENCES CORPORATION, a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies that: FIRST: This Certificate of Amendment amends the provisions of the Corporation’s Sixth Amended and Restated Certificate of Inc |
|
| June 12, 2023 |
AMENDMENT NO. 2 EXACT SCIENCES CORPORATION 2019 OMNIBUS LONG-TERM INCENTIVE PLAN EXHIBIT 10.1 AMENDMENT NO. 2 TO EXACT SCIENCES CORPORATION 2019 OMNIBUS LONG-TERM INCENTIVE PLAN This AMENDMENT NO. 2 (the “Amendment”) amends the 2019 Omnibus Long-Term Incentive Plan (as previously amended, the “Existing Plan”; as amended hereby, the “Plan”) of EXACT SCIENCES CORPORATION, a Delaware corporation (the “Company”). Statement of Purpose The Existing Plan was originally approved by th |
|
| June 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2023 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| June 12, 2023 |
Exhibit 3.2 SEVENTH AMENDED AND RESTATED BY-LAWS OF EXACT SCIENCES CORPORATION (As of June 9, 2023) BY-LAWS TABLE OF CONTENTS Page Article 1 STOCKHOLDERS 1 1.1 PLACE OF MEETINGS 1 1.2 ANNUAL MEETINGS 1 1.3 SPECIAL MEETINGS 1 1.4 NOTICE OF MEETINGS 1 1.5 VOTING LIST 2 1.6 QUORUM 2 1.7 ADJOURNMENTS, ETC 2 1.8 VOTING AND PROXIES 2 1.9 ACTION AT MEETING 3 1.10 INTRODUCTION OF BUSINESS AT MEETINGS 3 1. |
|
| May 25, 2023 |
Calculation of Filing Fee Tables ……Form S-3ASR…….. (Form Type) …………….…………… Exact Sciences Corporation ………………………….. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate A |
|
| May 25, 2023 |
Exhibit 25 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) ☐ U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 91-1821036 I.R.S. Emp |
|
| May 25, 2023 |
As Filed With the Securities and Exchange Commission on May 25, 2023 Table of Contents As Filed With the Securities and Exchange Commission on May 25, 2023 Registration No. |
|
| May 9, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35092 EXACT SCIENCES CORPORATION (Exact na |
|
| May 9, 2023 |
Exhibit 99 Investor Contact: Megan Jones Exact Sciences Corp. [email protected] 608-535-8815 Media Contact: Morry Smulevitz Exact Sciences Corp. [email protected] 608-345-8010 For Immediate Release Exact Sciences Announces First Quarter 2023 Results Reports record results, raises full-year guidance, accelerates path to positive free cash flow First quarter highlights •Total f |
|
| May 9, 2023 |
EXHIBIT 10.2 EXACT SCIENCES CORPORATION 2010 EMPLOYEE STOCK PURCHASE PLAN (As amended and restated on March 22, 2023) Article 1-Purpose. This 2010 Employee Stock Purchase Plan, as amended and restated (the "Plan"), is intended to encourage stock ownership by all eligible employees of Exact Sciences Corporation (the "Company"), a Delaware corporation, and its Participating Subsidiaries (as defined |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 9, 2023 |
Exact Sciences Corporation Non-Employee Director Compensation Policy EXHIBIT 10.3 Exact Sciences Corporation Non-Employee Director Compensation Policy The purpose of this Non-Employee Director Compensation Policy of Exact Sciences Corporation, a Delaware corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high caliber directors who are not employees or officers of the Company |
|
| April 26, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| April 14, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| March 17, 2023 |
Calculation of Filing Fee Tables ……424(b)(7)…….. (Form Type) …………….…………… Exact Sciences Corporation ………………………….. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum (2) Aggregate Offering Price |
|
| March 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2023 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| March 17, 2023 |
EXACT SCIENCES CORPORATION 5,171,577 Shares of Common Stock Table of Contents PROSPECTUS SUPPLEMENT (To prospectus dated June 1, 2020) EXACT SCIENCES CORPORATION 5,171,577 Shares of Common Stock This prospectus supplement relates to the resale of up to 5,171,577 shares of our common stock, par value $0. |
|
| March 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| March 1, 2023 |
EXHIBIT 4.2 EXACT SCIENCES CORPORATION 2.0% Convertible Senior Notes due 2030 FOURTH SUPPLEMENTAL INDENTURE Dated as of March 1, 2023 to INDENTURE Dated as of January 17, 2018 U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee TABLE OF CONTENTS Page ARTICLE 1 Scope of Fourth Supplemental Indenture; Definitions 1 SECTION 1.01. Scope of Fourth Supplemental Indenture 1 SECTION 1.02. Definition |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 1, 2023 |
Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes EXHIBIT 99.1 Investor Contact: Megan Jones Exact Sciences Corp. [email protected] 608-535-8815 Media Contact: Morry Smulevitz Exact Sciences Corp. [email protected] 608-345-8010 For Immediate Release Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes MADISON, Wis., Feb. 23, 2023 — Exact Sciences Corp. (Nasdaq: EXAS) (the “Comp |
|
| February 21, 2023 |
EXACT SCIENCES CORPORATION EQUITY AWARD DEATH, DISABILITY AND RETIREMENT POLICY EXHIBIT 10.32 EXACT SCIENCES CORPORATION EQUITY AWARD DEATH, DISABILITY AND RETIREMENT POLICY 1.Introduction. This Equity Award Death, Disability and Retirement Policy (the “Policy”) specifies the treatment of each outstanding equity award (an “Equity Award”) granted by Exact Sciences Corporation, a Delaware corporation (including any successor thereto, the “Company”), in the event of the Death, D |
|
| February 21, 2023 |
Exhibit 99 Investor Contact: Megan Jones Exact Sciences Corp. [email protected] 608-535-8815 Media Contact: Morry Smulevitz Exact Sciences Corp. [email protected] 608-345-8010 For Immediate Release Exact Sciences Announces Fourth Quarter 2022 Results Reports record revenue, expects revenue of $2,265-2,315 million and positive adjusted EBITDA for full year 2023 Fourth quarter |
|
| February 21, 2023 |
SUBSIDIARIES OF EXACT SCIENCES CORPORATION EXHIBIT 21 SUBSIDIARIES OF EXACT SCIENCES CORPORATION Registrant’s consolidated subsidiaries are shown below, together with the state or jurisdiction of organization of each subsidiary and the percentage of voting securities that Registrant owns in each subsidiary. |
|
| February 21, 2023 |
EXHIBIT 10.17 CONSULTING AGREEMENT This Consulting Agreement (the “Agreement”) is entered into between Exact Sciences Corporation, a Delaware corporation (the “Company”), and D. Scott Coward, an individual (“Consultant”). The Company desires to retain the services of Consultant and Consultant desires to provide consultation to the Company. In consideration of the mutual covenants and promises cont |
|
| February 21, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-35092 EXACT SCIENCES CORPORATION (Exact name of re |
|
| February 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| February 10, 2023 |
EXAS / EXACT Sciences Corporation / ARK Investment Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| February 9, 2023 |
EXAS / EXACT Sciences Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: Exact Sciences Corp. Title of Class of Securities: Common Stock CUSIP Number: 30063P105 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| February 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* EXACT SCIENCES CORPORATION (Name of Issuer) Common Stock (Title of Class of Securities) 30063P105 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| January 9, 2023 |
Exact Sciences Announces Preliminary Fourth Quarter 2022 Results Exhibit 99 Investor Contact: Megan Jones Exact Sciences Corp. [email protected] 608-535-8815 Media Contact: Morry Smulevitz Exact Sciences Corp. [email protected] 608-345-8010 For Immediate Release Exact Sciences Announces Preliminary Fourth Quarter 2022 Results Preliminary fourth quarter highlights: •Expected total fourth quarter revenue, excluding COVID-19 testing, increase |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2023 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2022 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| November 3, 2022 |
Exhibit 99 Investor Contact: Megan Jones Exact Sciences Corp. [email protected] 608-535-8815 Media Contact: Morry Smulevitz Exact Sciences Corp. [email protected] 608-345-8010 For Immediate Release Exact Sciences Announces Third Quarter 2022 Results Reports Record Revenue, Raises Full-Year Guidance, Accelerates Path to Profitability Third quarter highlights ?Total third quart |
|
| November 3, 2022 |
EXHIBIT 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (?Agreement?) is entered into effective as of 9/2/2022 (the ?Effective Date?), by and between Brian Baranick (?Employee?) and Exact Sciences Corporation, a Delaware corporation (the ?Company,? and together with Employee, the ?Parties?). WHEREAS, the Company desires to employ Employee as its General Manager, Precision Oncology, and Employe |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 3, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35092 EXACT SCIENCES CORPORATION (Exac |
|
| August 2, 2022 |
As filed with the Securities and Exchange Commission on August 2, 2022 As filed with the Securities and Exchange Commission on August 2, 2022 Registration No. |
|
| August 2, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35092 EXACT SCIENCES CORPORATION (Exact nam |
|
| August 2, 2022 |
Exact Sciences Announces Second Quarter 2022 Results Exhibit 99 Investor Contact: Megan Jones Exact Sciences Corp. [email protected] 608-535-8815 Media Contact: Morry Smulevitz Exact Sciences Corp. [email protected] 608-345-8010 For Immediate Release Exact Sciences Announces Second Quarter 2022 Results Second quarter highlights •Total second quarter revenue of $522 million, including Screening revenue of $354 million, Precision |
|
| August 2, 2022 |
EXHIBIT 107.1 Calculation of Filing Fee Tables ……Form S-8…….. (Form Type) …………….…………… Exact Sciences Corporation ………………………….. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offeri |
|
| August 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2022 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| June 30, 2022 |
EXHIBIT 10.3 Receivables Purchase Agreement dated as of June 29, 2022 by and among the Various Entities listed on Schedule I hereto, as Originators, Exact Sciences Laboratories, LLC, as the initial Servicer, and Exact Sciences Corporation, as Buyer Table of Contents Page ARTICLE I AGREEMENT TO PURCHASE AND SELL 2 SECTION 1.1 Agreement To Purchase and Sell 2 SECTION 1.2 Timing of Purchases 3 SECTIO |
|
| June 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2022 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 30, 2022 |
EXHIBIT 10.2 Receivables Purchase Agreement dated as of June 29, 2022 by and among Exact Sciences Corporation, as Seller, Exact Sciences Laboratories, LLC, as the initial Servicer, and Exact Receivables LLC, as Buyer Table of Contents Page ARTICLE I AGREEMENT TO PURCHASE AND SELL 2 SECTION 1.1 Agreement To Purchase and Sell 2 SECTION 1.2 Timing of Purchases 3 SECTION 1.3 Consideration for Purchase |
|
| June 30, 2022 |
EXHIBIT 10.1 Receivables Financing Agreement Dated as of June 29, 2022 by and among Exact Receivables LLC, as Borrower, The Persons from Time to Time Party Hereto, as Lenders and Group Agents, PNC Bank, National Association, as Administrative Agent, Exact Sciences Laboratories, LLC, as initial Servicer and PNC Capital Markets LLC, as Structuring Agent Table of Contents Section Heading Page Article |
|
| June 29, 2022 |
Table of Contents United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2021 OR ? TRANSITION REPORT PUR |
|
| June 10, 2022 |
EXHIBIT 10.2 EXACT SCIENCES CORPORATION 2010 EMPLOYEE STOCK PURCHASE PLAN (As amended and restated on June 9, 2022) Article 1?Purpose. This 2010 Employee Stock Purchase Plan, as amended and restated (the "Plan"), is intended to encourage stock ownership by all eligible employees of Exact Sciences Corporation (the "Company"), a Delaware corporation, and its Participating Subsidiaries (as defined in |
|
| June 10, 2022 |
AMENDMENT NO. 1 EXACT SCIENCES CORPORATION 2019 OMNIBUS LONG-TERM INCENTIVE PLAN EXHIBIT 10.1 AMENDMENT NO. 1 TO EXACT SCIENCES CORPORATION 2019 OMNIBUS LONG-TERM INCENTIVE PLAN This AMENDMENT NO. 1 (the ?Amendment?) amends the 2019 OMNIBUS LONG TERM INCENTIVE PLAN (the ?Existing Plan?; as amended hereby, the ?Plan?) of EXACT SCIENCES CORPORATION, a Delaware corporation (the ?Company?). Statement of Purpose The Existing Plan was originally approved by the Company?s Board of Di |
|
| June 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2022 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the registrant ? Filed by a party other than the registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive |
|
| May 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2022 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 2, 2022 |
Calculation of Filing Fee Tables ??424(b)(7)??.. (Form Type) ?????.????? Exact Sciences Corporation ??????????.. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum (2) Aggregate Offering Price |
|
| May 2, 2022 |
EXACT SCIENCES CORPORATION 265,186 Shares of Common Stock Table of Contents PROSPECTUS SUPPLEMENT (To prospectus dated June 1, 2020) EXACT SCIENCES CORPORATION 265,186 Shares of Common Stock This prospectus supplement relates to the resale of up to 265,186 shares of our common stock, par value $0. |
|
| April 29, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.??????)? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 26, 2022 |
Exact Sciences announces first quarter 2022 results Exhibit 99 Investor Contact: Megan Jones Exact Sciences Corp. [email protected] 608-535-8815 Media Contact: Katie Boyce Exact Sciences Corp. [email protected] 608-710-3903 For Immediate Release Exact Sciences announces first quarter 2022 results ?Total first quarter revenue of $487M, including Screening revenue of $307M, Precision Oncology revenue of $153M, and COVID-19 testing r |
|
| April 26, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35092 EXACT SCIENCES CORPORATION (Exact na |
|
| April 26, 2022 |
Exact Sciences Corporation Non-Employee Director Compensation Policy EXHIBIT 10.2 Exact Sciences Corporation Non-Employee Director Compensation Policy The purpose of this Non-Employee Director Compensation Policy of Exact Sciences Corporation, a Delaware corporation (the ?Company?), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high caliber directors who are not employees or officers of the Company |
|
| April 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2022 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 26, 2022 |
EXHIBIT 10.1 EXACT SCIENCES CORPORATION 2010 EMPLOYEE STOCK PURCHASE PLAN (As amended and restated on March 11, 2022) Article 1?Purpose. This 2010 Employee Stock Purchase Plan, as amended and restated (the "Plan"), is intended to encourage stock ownership by all eligible employees of Exact Sciences Corporation (the "Company"), a Delaware corporation, and its Participating Subsidiaries (as defined |
|
| February 22, 2022 |
EXHIBIT 10.15 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (?Agreement?) is entered into effective as of October 11, 2021 (the ?Effective Date?), by and between Everett Cunningham (?Employee?) and Exact Sciences Corporation, a Delaware corporation (the ?Company,? and together with Employee, the ?Parties?). WHEREAS, the Company desires to employ Employee as its Executive Vice President, Head of S |
|
| February 22, 2022 |
Exact Sciences Announces Fourth Quarter 2021 Results Exhibit 99 Investor Contact: Megan Jones Exact Sciences Corp. [email protected] 608-535-8815 Media Contact: Katie Boyce Exact Sciences Corp. [email protected] 608-710-3903 For Immediate Release Exact Sciences Announces Fourth Quarter 2021 Results ?Total fourth quarter revenue of $474M, including Screening revenue of $278M, Precision Oncology revenue of $149M, and COVID-19 testing |
|
| February 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2022 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| February 22, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-35092 EXACT SCIENCES CORPORATION (Exact name of re |
|
| February 22, 2022 |
SUBSIDIARIES OF EXACT SCIENCES CORPORATION EXHIBIT 21 SUBSIDIARIES OF EXACT SCIENCES CORPORATION Registrant?s consolidated subsidiaries are shown below, together with the state or jurisdiction of organization of each subsidiary and the percentage of voting securities that Registrant owns in each subsidiary. |
|
| February 11, 2022 |
EXAS / EXACT Sciences Corporation / Capital World Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Exact Sciences Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 30063P105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| February 10, 2022 |
EXAS / EXACT Sciences Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Exact Sciences Corp. Title of Class of Securities: Common Stock CUSIP Number: 30063P105 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| February 9, 2022 |
EXAS / EXACT Sciences Corporation / ARK Investment Management LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| February 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* EXACT SCIENCES CORPORATION (Name of Issuer) Common Stock (Title of Class of Securities) 30063P105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| January 28, 2022 |
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2022 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 28, 2022 |
SIXTH AMENDED AND RESTATED EXACT SCIENCES CORPORATION (As of January 25, 2022) TABLE OF CONTENTS Exhibit 3.1 SIXTH AMENDED AND RESTATED BY-LAWS OF EXACT SCIENCES CORPORATION (As of January 25, 2022) BY-LAWS TABLE OF CONTENTS Page Article 1 - STOCKHOLDERS 1 1.1 PLACE OF MEETINGS 1 1.2 ANNUAL MEETING 1 1.3 SPECIAL MEETINGS 1 1.4 NOTICE OF MEETINGS 1 1.5 VOTING LIST 1 1.6 QUORUM 1 1.7 ADJOURNMENTS, ETC 2 1.8 VOTING AND PROXIES 2 1.9 ACTION AT MEETING 2 1.10 INTRODUCTION OF BUSINESS AT MEETINGS 3 |
|
| January 10, 2022 |
Exhibit 99.3 Exact Sciences and OncXerna Announce Licensing Agreement to Help Predict Immunotherapy Response for More Patients Agreement grants a license to Exact Sciences for OncXerna?s Xerna? TME Panel adding to its comprehensive tumor profiling solution, GEM ExTra? Arrangement expands Exact Sciences? ability to support immuno-oncology clinical development programs MADISON, Wis., and WALTHAM, Ma |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2022 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 10, 2022 |
CALCULATION OF REGISTRATION FEE Table of Contents Filed Pursuant to Rule 424(b)(7) Registration No. 333-238845 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered (1) Proposed Maximum Offering Price per share (2) Proposed Maximum Aggregate Offering Price (2) Amount of Registration Fee (3) Common Stock, par value $0.01 per share 1,070,410 $73.86 $79,060,483 $7,328.91 (1) Purs |
|
| January 10, 2022 |
Exact Sciences Announces Preliminary Fourth Quarter 2021 Results Exhibit 99.1 Investor Relations Contact: Megan Jones [email protected] 608-535-8815 Media Contact: Katie Boyce [email protected] 608-710-3903 For Immediate Release Exact Sciences Announces Preliminary Fourth Quarter 2021 Results ?Expected total fourth quarter revenue of $472-475M, including Screening revenue of $277-278M, Precision Oncology revenue of $148.5-149.5M, and COVID-19 |
|
| January 10, 2022 |
Exhibit 99.2 Exact Sciences Acquires PreventionGenetics to Accelerate Availability of Hereditary Cancer Testing for More Patients PreventionGenetics? comprehensive genetic testing portfolio complements Exact Sciences? advanced cancer tests, enabling disease prevention and earlier cancer detection to benefit patients across decades of life Foundational laboratory and skilled team with experience in |
|
| November 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2021 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| November 2, 2021 |
Exact Sciences announces third quarter 2021 results Exhibit 99 Investor Contact: Megan Jones Exact Sciences Corp. [email protected] 608-535-8815 Media Contact: Katie Boyce Exact Sciences Corp. [email protected] 608-710-3903 For Immediate Release Exact Sciences announces third quarter 2021 results MADISON, Wis., November 2, 2021 - Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $456.4 milli |
|
| November 2, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35092 EXACT SCIENCES CORPORATION (Exac |
|
| November 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2021 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission |
|
| September 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2021 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| July 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2021 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) DE 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| July 28, 2021 |
Exact Sciences Announces Second Quarter 2021 Results EX-99 2 exas-20210728xex99.htm EX-99 Exhibit 99 Investor Contact: Megan Jones Exact Sciences Corp. [email protected] 608-535-8815 Media Contact: Katie Boyce Exact Sciences Corp. [email protected] 608-710-3903 For Immediate Release Exact Sciences Announces Second Quarter 2021 Results MADISON, Wis., July 28, 2021 — Exact Sciences Corp. (Nasdaq: EXAS) today announced that the compan |
|
| July 28, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35092 EXACT SCIENCES CORPORATION (Exact nam |
|
| July 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2021 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 29, 2021 |
Table of Contents United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2020 OR ? TRANSITION REPORT PUR |
|
| June 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2021 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| June 7, 2021 |
CALCULATION OF REGISTRATION FEE 424B7 1 exas-20210519x424b7.htm 424B7 Table of Contents Filed Pursuant to Rule 424(b)(7) Registration No. 333-238845 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered (1) Proposed Maximum Offering Price per share (2) Proposed Maximum Aggregate Offering Price (2) Amount of Registration Fee (3) Common Stock, par value $0.01 per share 125,444 $ |
|
| May 4, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35092 EXACT SCIENCES CORPORATION (Exact na |
|
| May 4, 2021 |
Exact Sciences Announces First Quarter 2021 Results Exhibit 99 Investor Contact: Megan Jones Exact Sciences Corp. [email protected] 608-535-8815 Media Contact: Katie Boyce Exact Sciences Corp. [email protected] 608-710-3903 For Immediate Release Exact Sciences Announces First Quarter 2021 Results MADISON, Wis., May 4, 2021 ? Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $402.1 million fo |
|
| May 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2021 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) DE 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2021 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 29, 2021 |
Schedule 14A filed on April 29, 202 Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2021 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| March 3, 2021 |
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2021 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| March 3, 2021 |
FIFTH AMENDED AND RESTATED EXACT SCIENCES CORPORATION (As of March 3, 2021) TABLE OF CONTENTS Exhibit 3.1 FIFTH AMENDED AND RESTATED BY-LAWS OF EXACT SCIENCES CORPORATION (As of March 3, 2021) BY-LAWS TABLE OF CONTENTS Page Article 1 - STOCKHOLDERS 1 1.1 PLACE OF MEETINGS 1 1.2 ANNUAL MEETING 1 1.3 SPECIAL MEETINGS 1 1.4 NOTICE OF MEETINGS 1 1.5 VOTING LIST 1 1.6 QUORUM 2 1.7 ADJOURNMENTS, ETC 2 1.8 VOTING AND PROXIES 2 1.9 ACTION AT MEETING 2 1.10 INTRODUCTION OF BUSINESS AT MEETINGS 3 1. |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Exact Sciences Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 30063P105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch |
|
| February 16, 2021 |
Exact Sciences Announces Fourth Quarter 2020 Results EX-99 2 exas-20210216xex99.htm EX-99 Exhibit 99 Investor Contact: Megan Jones Exact Sciences Corp. [email protected] 608-535-8815 Media Contact: Katie Boyce Exact Sciences Corp. [email protected] 608-710-3903 For Immediate Release Exact Sciences Announces Fourth Quarter 2020 Results MADISON, Wis., Feb. 16, 2021 — Exact Sciences Corp. (Nasdaq: EXAS) today announced that the compan |
|
| February 16, 2021 |
Exact Sciences Corporation Non-Employee Director Compensation Policy EX-10.25 5 exas-20201231xex1025.htm EX-10.25 Exhibit 10.25 Exact Sciences Corporation Non-Employee Director Compensation Policy The purpose of this Non-Employee Director Compensation Policy of Exact Sciences Corporation, a Delaware corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high caliber directors who |
|
| February 16, 2021 |
Exhibit 10.16 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (?Agreement?) is entered into effective as of August 22, 2017 (the ?Effective Date?), by and between Sarah Condella (?Employee?) and Exact Sciences Corporation, a Delaware corporation (the ?Company,? and together with Employee, the ?Parties?). WHEREAS, the Company desires to employ Employee as its Senior Vice President, Human Resources, |
|
| February 16, 2021 |
Exhibit 10.17 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (?Agreement?) is entered into effective as of August 28, 2017 (the ?Effective Date?), by and between Ana Hooker (?Employee?) and Exact Sciences Corporation, a Delaware corporation (the ?Company,? and together with Employee, the ?Parties?). WHEREAS, the Company desires to employ Employee as its Senior Vice President, Operations, and Emplo |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2021 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| February 16, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-35092 EXACT SCIENCES CORPORATION (Exact name of re |
|
| February 16, 2021 |
SUBSIDIARIES OF EXACT SCIENCES CORPORATION EX-21 6 exas-20201231xexx21.htm EX-21 EXHIBIT 21 SUBSIDIARIES OF EXACT SCIENCES CORPORATION Registrant’s consolidated subsidiaries are shown below, together with the state or jurisdiction of organization of each subsidiary and the percentage of voting securities that Registrant owns in each subsidiary. Name of Subsidiary Jurisdiction of Incorporation or Organization Percent of Outstanding Voting S |
|
| February 16, 2021 |
EX-4.6 2 exas-20201231xex46.htm EX-4.6 Exhibit 4.6 DESCRIPTION OF COMMON STOCK OF EXACT SCIENCES CORPORATION REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following information is a summary of information concerning the common stock, par value $0.01 per share (the “Common Stock”), of Exact Sciences Corporation (“we,” “our,” “us,” or the “Company”) and does not purpor |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Exact Sciences Corp. Title of Class of Securities: Common Stock CUSIP Number: 30063P105 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| January 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2021 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 11, 2021 |
Exact Sciences Announces Preliminary Fourth Quarter 2020 Results Exhibit 99.1 Investor Relations Contact: Megan Jones [email protected] 608-535-8815 Media Contact: Katie Boyce [email protected] 608-710-3903 For Immediate Release Exact Sciences Announces Preliminary Fourth Quarter 2020 Results •Expected total revenue of $464.5-467.5M, including Screening revenue of $249-250M, Precision Oncology revenue of $117-118M, and COVID-19 testing revenue |
|
| January 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2021 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 5, 2021 |
THRIVE EARLIER DETECTION CORP. 2019 STOCK OPTION AND GRANT PLAN EX-4.6 2 exas-20210105xex46.htm EX-4.6 Exhibit 4.6 THRIVE EARLIER DETECTION CORP. 2019 STOCK OPTION AND GRANT PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Thrive Earlier Detection Corp. 2019 Stock Option and Grant Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, directors and Consultants of Thrive Earlier Detecti |
|
| January 5, 2021 |
S-8 1 exas-20210105xsx8.htm S-8 As filed with the Securities and Exchange Commission on January 5, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 EXACT SCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation |
|
| January 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2021 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 5, 2021 |
Second Amendment to Agreement and Plan of Merger dated January 4, 2021 Exhibit 2.2 SECOND AMENDMENT TO AGREEMENT AND PLAN OF MERGER This SECOND AMENDMENT TO AGREEMENT AND PLAN OF MERGER (this “Amendment”) is made and entered into as of January 4, 2021, by and among: (i) Exact Sciences Corporation, a Delaware corporation (“Parent”); (ii) Eagle Merger Sub I, Inc., a Delaware corporation and a wholly-owned, direct subsidiary of Parent (“First Merger Sub”); (iii) Eagle M |
|
| January 5, 2021 |
Exhibit 99.1 Exact Sciences Contacts Investor Relations: Megan Jones [email protected] 608-535-8815 Media: Katie Boyce [email protected] 608-710-3903 For Immediate Release Exact Sciences Completes Acquisition of Thrive Earlier Detection, Creating a Leader in Blood-Based, Multi-Cancer Screening MADISON, Wis., – January 5, 2021 – Exact Sciences Corp. (Nasdaq: EXAS) today announced |
|
| January 5, 2021 |
CALCULATION OF REGISTRATION FEE Table of Contents Filed Pursuant to Rule 424(b)(7) Registration No. 333-238845 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered (1) Proposed Maximum Offering Price per share (2) Proposed Maximum Aggregate Offering Price (2) Amount of Registration Fee (3) Common Stock, par value $0.01 per share 9,323,266 $129.00 $1,202,701,314 $131,214.71 (1 |
|
| January 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2021 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 5, 2021 |
First Amendment to Agreement and Plan of Merger dated December 23, 2020 Exhibit 2.1 AMENDMENT TO AGREEMENT AND PLAN OF MERGER This AMENDMENT TO AGREEMENT AND PLAN OF MERGER (this “Amendment”) is made and entered into as of December 23, 2020, by and among: (i) Exact Sciences Corporation, a Delaware corporation (“Parent”); (ii) Eagle Merger Sub I, Inc., a Delaware corporation and a wholly-owned, direct subsidiary of Parent (“First Merger Sub”); (iii) Eagle Merger Sub II |
|
| November 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2020 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| October 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2020 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission |
|
| October 27, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35092 EXACT SCIENCES CORPORATION (Exac |
|
| October 27, 2020 |
EX-99.1 3 tm2034190d2ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE EXACT SCIENCES TO ACQUIRE THRIVE, BECOMING A LEADER IN BLOOD-BASED, MULTI-CANCER SCREENING Brings Together Cancer Screening R&D Pioneers to Transform the Future of Cancer Diagnostics and Impact Lives Combines Thrive’s CancerSEEK with Exact Sciences’ Best-in-Class Platforms and Infrastructure to Accelerate Approval, Ava |
|
| October 27, 2020 |
CALCULATION OF REGISTRATION FEE TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(2) Registration No. 333-238845 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered Proposed Maximum Offering Price per Share Proposed Maximum Aggregate Offering Price Amount of Registration Fee(1) Common Stock, par value $0.01 per share 8,605,483 $ 101.00 $ 869,153,783 $ 94,825 (1) Calculated in |
|
| October 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2020 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission |
|
| October 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2020 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) DE 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| October 27, 2020 |
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH SECOND AMENDED AND RESTATED LICENSE AGREEMENT EX-10.1 2 a0930202010-qexhibit101.htm EX-10.1 CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. EXHIBIT 10.1 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH SECOND AMENDED AND RESTATED LICENSE AGREEMENT This Second Amended and Restated License Agreement (thi |
|
| October 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2020 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission |
|
| October 27, 2020 |
EX-2.1 2 tm2034190d2ex2-1.htm EXHIBIT 2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER BY AND AMONG EXACT SCIENCES CORPORATION, EAGLE MERGER SUB I, INC., EAGLE MERGER SUB II, LLC, THRIVE EARLIER DETECTION CORP. AND shareholder representative services llc, SOLELY IN ITS CAPACITY AS REPRESENTATIVE OF THE SELLERS Dated as of October 26, 2020 TABLE OF CONTENTS Page Article I DEFINITIONS 1.1 General 2 1.2 |
|
| October 27, 2020 |
Exhibit 99.1 Investor Relations Contact: Megan Jones Exact Sciences Corp. [email protected] 608-535-8815 For Immediate Release Exact Sciences Announces Entry into Agreements to Sell $870 million of Common Stock in Registered Direct Offering MADISON, Wis., October 27, 2020 – Exact Sciences Corporation (Nasdaq: EXAS) today announced the entry into agreements to sell an aggregate of 8,605, |
|
| October 27, 2020 |
Exact Sciences Announces Third Quarter 2020 Results Exhibit 99 Investor Contact: Megan Jones Exact Sciences Corp. [email protected] 608-535-8815 Media Contact: Cara Connelly Exact Sciences Corp. [email protected] 608-284-5735 For Immediate Release Exact Sciences Announces Third Quarter 2020 Results MADISON, Wis., October 27, 2020 — Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $408.4 |
|
| October 7, 2020 |
EX-10.1 2 tm2032631d1ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 AMENDED & RESTATED COLOGUARD® PROMOTION AGREEMENT BY AND BETWEEN EXACT SCIENCES CORPORATION AND PFIZER INC. October 6, 2020 TABLE OF CONTENTS Page 1. DEFINITIONS 1 2. GOVERNANCE 11 2.1 Joint Steering Committee 11 2.2 Joint Operations Committee 14 2.3 Joint Review Committee 15 2.4 Finance Representative 16 2.5 Alliance Managers 16 2.6 Compli |
|
| October 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2020 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission |
|
| September 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2020 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| July 31, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35092 EXACT SCIENCES CORPORATION (Exact nam |
|
| July 31, 2020 |
AMENDMENT NO. 1 TO CONSTRUCTION LOAN AGREEMENT AND CONSTRUCTION NOTE Exhibit 10.3 AMENDMENT NO. 1 TO CONSTRUCTION LOAN AGREEMENT AND CONSTRUCTION NOTE THIS AMENDMENT NO. 1 TO CONSTRUCTION LOAN AGREEMENT, effective as of June 30, 2020 (this "Amendment"), is by and between FIFTH THIRD BANK, NATIONAL ASSOCIATION, successor in interest to MB Financial Bank, N.A. (the "Bank"), and CG GROWTH, LLC, a Wisconsin limited liability company (the “Borrower”), amends and supplem |
|
| July 31, 2020 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (“Agreement”) is entered into effective as of April 20, 2020 (the “Effective Date”), by and between Gisela Paulsen (“Employee”) and Exact Sciences Corporation, a Delaware corporation (the “Company,” and together with Employee, the “Parties”). WHEREAS, the Company desires to employ Employee as its General Manager, Precision Oncology, and E |
|
| July 31, 2020 |
Exact Sciences Corporation Non-Employee Director Compensation Policy Exhibit 10.2 Exact Sciences Corporation Non-Employee Director Compensation Policy The purpose of this Non-Employee Director Compensation Policy of Exact Sciences Corporation, a Delaware corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high caliber directors who are not employees or officers of the Company |
|
| July 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2020 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) DE 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| July 30, 2020 |
Exact Sciences Announces Second Quarter 2020 Results Exhibit 99 Investor Contact: Megan Jones Exact Sciences Corp. [email protected] 608-535-8815 Media Contact: Cara Connelly Exact Sciences Corp. [email protected] 608-284-5735 For Immediate Release Exact Sciences Announces Second Quarter 2020 Results MADISON, Wis., July 30, 2020 — Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $268.9 mi |
|
| July 24, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2020 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| July 24, 2020 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF EXACT SCIENCES CORPORATION EXACT SCIENCES CORPORATION, a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies that: FIRST: This Certificate of Amendment amends the provisions of the Corporation’s Sixth Amended and Restated Certificate of Inc |
|
| June 29, 2020 |
Table of Contents United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One) ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2019 OR TRANSITION REPORT PUR |
|
| June 2, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2020 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| June 2, 2020 |
CALCULATION OF REGISTRATION FEE Table of Contents Filed Pursuant to Rule 424(b)(7) Registration No. 333-238845 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered (1) Proposed Maximum Offering Price per Unit Proposed Maximum Aggregate Offering Price Amount of Registration Fee Common Stock, par value $0.01 per share 395,627 $— (2) $— (2) $— (2) (1) Pursuant to Rule 416(a) und |
|
| June 1, 2020 |
EX-4.4 2 exhibit-44.htm EX-4.4 Exhibit 4.4 |
|
| June 1, 2020 |
EXACT SCIENCES CORPORATION Dated as of ___________ ___, 2020 as Trustee EX-4.7 3 exhibit47.htm EX-4.7 Exhibit 4.7 EXACT SCIENCES CORPORATION INDENTURE Dated as of , 2020 , as Trustee Reconciliation and tie between Indenture, dated as of , 2020, and the Trust Indenture Act of 1939, as amended. Trust Indenture Act of 1939 Section Indenture Section 310(a)(1) 6.11 (a)(2) 6.11 (a)(3) TIA (a)(4) Not Applicable (a)(5) TIA (b) 6.9; 6.11; TIA 311(a) TIA (b) TIA 312(a) 6.7 (b) |
|
| June 1, 2020 |
Table of Contents As Filed With the Securities and Exchange Commission on June 1, 2020 Registration No. |
|
| May 6, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35092 EXACT SCIENCES CORPORATION (Exact na |
